Publicacións (42) Publicacións nas que participase algún/ha investigador/a

2013

  1. A 10-year step forward in hereditary cancer in Spain

    Clinical and Translational Oncology

  2. A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer

    BMC Genomics, Vol. 14

  3. Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: Results from a randomized, phase II prospective trial

    Annals of Oncology, Vol. 24, Núm. 2, pp. 448-453

  4. Adrenal carcinoma: A retrospective analysis of our series

    Endocrinologia y Nutricion

  5. Analysis of PALB2 Gene in BRCA1/BRCA2 Negative Spanish Hereditary Breast/Ovarian Cancer Families with Pancreatic Cancer Cases

    PLoS ONE, Vol. 8, Núm. 7

  6. Application of biotechnology in myocardial regeneration-tissue engineering triad: Cells, scaffolds, and signaling molecules

    BioMed Research International

  7. Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer

    Journal of Geriatric Oncology, Vol. 4, Núm. 2, pp. 114-121

  8. Black-pigmented sputum

    Journal of Cytology, Vol. 30, Núm. 4, pp. 274-275

  9. C-terminal-PEDF reduces IC50 doses and chemoresistant population of CD133 and BCRP1-positve cancer stem like cells

    Journal of Analytical Oncology, Vol. 2, Núm. 4, pp. 195-208

  10. Class II Phosphoinositide 3-Kinases Contribute to Endothelial Cells Morphogenesis

    PLoS ONE, Vol. 8, Núm. 1

  11. Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

    Clinical and Translational Oncology, Vol. 15, Núm. 6, pp. 425-433

  12. Consenso en cáncer hereditario entre la Sociedad Española de Oncología Médica y las sociedades de atención primaria

    Semergen: revista española de medicina de familia, Núm. 5, pp. 259-266

  13. Cáncer de pulmón en el área sanitaria de Pontevedra: incidencia, presentación clínica y supervivencia

    Anales del sistema sanitario de Navarra, Vol. 36, Núm. 2, pp. 217-227

  14. Dolor como factor predictor de depresión en el paciente oncológico: estudio de casos y controles. Estudio D-PRESS

    Revista de la Sociedad Espanola del Dolor, Vol. 20, Núm. 3, pp. 113-121

  15. E2F1 loss induces spontaneous tumour development in Rb-deficient epidermis

    Oncogene, Vol. 32, Núm. 24, pp. 2937-2951

  16. Erratum: Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor (Clinical and Translational Oncology DOI: 10.1007/s12094-012-0985-x)

    Clinical and Translational Oncology

  17. FX enzyme and GDP-L-Fuc transporter expression in colorectal cancer

    Histopathology, Vol. 63, Núm. 2, pp. 174-186

  18. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study

    Journal of Clinical Oncology

  19. Gemcitabine and capecitabine as third- or later-line therapy for refractory advanced colorectal cancer: A retrospective study

    Anticancer Research, Vol. 33, Núm. 9, pp. 4089-4096

  20. Genetic study confirms association of HLA-DPA1*01:03 subtype with ankylosing spondylitis in HLA-B27-positive populations

    Human Immunology, Vol. 74, Núm. 6, pp. 764-767